Present-day NCCN guidelines propose brentuximab vedotin as servicing therapy for 1 yr immediately after superior-dose therapy with autologous stem mobile rescue (HDT/ASCR). The commonest secondary malignancy next treatment for Hodgkin lymphoma is lung cancer. The two chemotherapy with alkylating brokers and irradiation are linked to a ten-fold increased relative danger https://www.medebound.com/guide/419